U.S. inspectors recently uncovered new manufacturing problems at an Eli Lilly plant that has been under scrutiny by federal investigators.…
Der Wachstumsmarkt rund um die sogenannte Abnehmspritze sorgte 2023 bei den führenden Unternehmen Eli Lilly und Novo Nordisk für massive…
Investors were a bit concerned about an industrywide move.…
Todays Research Daily features new research reports on 16 major stocks, including Eli Lilly and Company (LLY), Linde plc (LIN)…
Wall Street has been focused on Novo Nordisk, Eli Lilly and other large drugmakers hoping to join the weight loss…
Taking a position in a life science exchange-traded fund (ETF) provides exposure to a basket of stocks focused on the…
ADDvise Group’s subsidiary Labplan has received an order from the pharmaceutical company Eli Lilly.
The order is worth approximately EUR 2.1…
For different reasons, both Eli Lilly and UnitedHealth are doing well enough to enact substantial dividend raises.…
For different reasons, both Eli Lilly and UnitedHealth are doing well enough to enact substantial dividend raises.…
Eli Lilly, Novo Nordisk, Amgen and AstraZeneca are included in this Analyst Blog.…
Novo Nordisk may dominate the weight management space, but pharma giant Eli Lilly is quickly gaining steam.…
Eli Lilly is moving as LLY stock is at an all time high. Stryker stock is also at an all-time…
Nvidia, Eli Lilly and Palo Alto Networks — all top performers last year — are leading the portfolio in the…
…
Eli Lilly has no plans to ease up on R&D spending. Meanwhile, Danaher continues to await an inflection point, while…
…
From Alphabet and BYD to Eli Lilly and Vivendi, keep an eye on these global stocks this year.…
LillyDirect is the latest attempt to simplify what critics call a complex system for distributing, pricing and prescribing prescription drugs.…
Eli Lilly (LLY) launches a new direct-to-consumer website to provide easy access to its medicines. Novo Nordisk (NVO) announces two…
Eli Lillys (LLY) digital pharmacy is expected to provide patients easy access to its FDA-approved tirzepatide medicines, Mounjaro and Zepbound.…
WWs revenue was sliding even before Ozempic came on the scene. Now Eli Lilly has a new weight loss drug…
The latest catalyst for Eli Lilly is a corporate decision more common in the retail and entertainment industries, not pharmaceuticals.…
…
These are the stocks posting the largest moves in midday trading.…
Eli Lilly and Co (NYSE:LLY) shares have gained more than 8% during the past five trading sessions on investor enthusiasm…
Eli Lilly is looking to deliver its anti-obesity treatments directly to consumers while warning against their use for cosmetic weight…
…
The platform, called LillyDirect, joins a growing field of websites offering telehealth prescriptions for weight loss drugs.…
Eli Lilly stock rally extends as BofA names it top biopharma pick for 2024…
Eli Lilly shares advanced in the double digits last year.…
Eli Lilly shares advanced in the double digits last year.…
The Nasdaq extended a losing streak while Bitcoin retreated. Eli Lilly was a winner again.…
Im Plus liegt gegenwärtig die Eli Lilly-Aktie . Zuletzt zahlten Investoren für das Wertpapier 616,69 US-Dollar. Die Eli Lilly-Aktie verzeichnet…
The past three years were bliss for Eli Lilly shareholders, but those not already on board should look at its…
…
The past three years were bliss for Eli Lilly shareholders, but those not already on board should look at its…
Here are Wednesdays biggest calls on Wall Street.…
…
Lilly (LLY) is making rapid pipeline progress in areas like obesity, diabetes and Alzheimers. Mounjaro and Zepbound are expected to…
Investors shouldnt assume Eli Lillys stock has peaked.…
Investors shouldnt assume Eli Lillys stock has peaked.…
…
Eli Lillys Point Biopharma acquisition doesnt change our optimism on the diabetes-and-obesity drug giant heading into the new year.…
After climbing 55% in 2023, Eli Lillys stock still has room to grow.…
…
…
Dublin, Dec. 22, 2023 (GLOBE NEWSWIRE) -- The "Global Injection Pen Market: Analysis By Type, By Therapy, By…
…
…
The obesity drugs that powered huge investor gains in 2023 are poised to inspire more corporate dealmaking, scientific breakthroughs and…